• Biophytis filed to register a Hong Kong joint venture with Asian partners led by China’s Ronghui Renhe Life Technology.
• The venture, Biophytis Biopharmaceutical Holding LTD, targets development and commercialization of BIO101 for sarcopenia in Asian markets.
• Closing is expected in coming weeks; Asian partners to fund an initial USD 3 million toward a USD 20 million total commitment.
• Biophytis to contribute patents plus a BIO101 license covering China, Japan, South Korea.
• Post-closing priorities include preparing an Asia phase 3 sarcopenia trial, regulatory filings, local hiring.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biophytis SA published the original content used to generate this news brief on June 02, 2026, and is solely responsible for the information contained therein.